ASX:OCCPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Orthocell Ltd
$0.770
Day Range
$0.760 – $0.790
52 Week Range
$0.700 – $1.600
Volume
7.92K
Avg Volume (10D)
313.04K
Market Cap
$209.64M
Price Chart
Market Statistics
Open$0.790
Previous Close$0.770
Day High$0.790
Day Low$0.760
52 Week High$1.600
52 Week Low$0.700
Valuation
Market Cap209.64M
Shares Outstanding272.25M
Price to Book5.08
Trading Activity
Volume7.92K
Value Traded6.09K
Bid$0.760 × 37,570
Ask$0.770 × 4,907
Performance
1 Day-3.14%
5 Day1.32%
13 Week-1.28%
52 Week-36.10%
YTD-29.03%
Technical Indicators
RSI (14)45.97
50-Day SMA$0.836
200-Day SMA$0.994
Latest News
Biotechnology
Orthocell Secures Access to 221 US Military & VA Medical Centres for Remplir
Orthocell wins access to 221 US DoD/VA centres for Remplir, a major US market expansion as HY26 revenue hits A$6.2m and cash sits at A$49.4m.
Biotechnology
Orthocell's Remplir Device Used in 23 Ukrainian Soldier Surgeries, Validating Field Utility
Orthocell's Remplir validated after 23 Ukrainian surgeries, boosting defence-market traction and global expansion; HY26 revenue +49%, cash ~A$49m.
Biotechnology
Orthocell Appoints Exclusive Remplir Distributor Ahead of UK Rollout
Orthocell names LEDA Orthopaedics exclusive UK distributor for Remplir ahead of regulatory approval, signaling rapid UK rollout and market prep.
Biotechnology
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.